October 14, 2021 Environ, Ag./Food & Bev Licensing, IP, and Legal Life Science Tools

Clear Labs Automated NGS Technology Platform (Clear Safety™) Approved by USDA’s National Poultry Improvement Plan for Salmonella Detection

Leader in Next-Generation Sequencing Workflow Automation Gains Agency Accreditation for Animal Health Testing SAN CARLOS, CALIF. (PRWEB) OCTOBER 14, 2021 Today, Clear Labs, a leader in providing fully automated, next-generation sequencing (NGS) platforms for turnkey diagnostics, is announcing that Clear Safety Salmonella has been approved by the National Poultry Improvement Plan (NPIP) for interim use in the detection of... Read more

October 14, 2021 Bio/Pharma/CRO Lab Equipment Lab Top-10 M&A, Partnerships

PerkinElmer Collaborates With Leading Life Science Incubators LabCentral and MBC BioLabs to Help Further Drug Discovery

Will provide automated protein characterization, cell imaging and cell counting technologies, along with expertise and training October 14, 2021 WHAT: PerkinElmer, Inc. a global leader committed to innovating for a healthier world, today announced it is collaborating with leading life science incubators LabCentral in Boston, Massachusetts and MBC BioLabs in San Francisco, California to provide... Read more

October 14, 2021 Uncategorized

Xylem Calls on Water Sector to Join “Race to Zero” Emissions Commitment

Targets the 10% of Global Emissions Generated by Water Use and Management RYE BROOK, N.Y.–(BUSINESS WIRE)–Oct. 14, 2021– Global water technology company, Xylem (NYSE:XYL), today called on water sector leaders and organizations to join a global sustainability push to reduce greenhouse gas emissions related to water systems and water management. The encouragement comes after last... Read more

October 14, 2021 PAI Top-10 Product Launch

New four-year data show Roche's ENSPRYNG significantly reduces debilitating relapses in people with neuromyelitis optica spectrum disorder

New data demonstrate ENSPRYNG’s robust and sustained longer-term efficacy in preventing relapses in people with neuromyelitis optica spectrum disorder (NMOSD) More than 70% of people treated with ENSPRYNG remained relapse-free after four years in the SAkuraStar (73%) and SAkuraSky (71%) open-label extension (OLE) studies, with a favourable safety profile ENSPRYNG is now approved in 58... Read more

October 14, 2021 PAI Top-10

Roche’s Gazyvaro shorter 90-minute infusion time approved in Europe for people with previously treated or untreated follicular lymphoma

Basel, 14 October 2021 Short duration infusion of Gazyvaro® (obinutuzumab) is administered with a target infusion time of 90 minutes, compared to the current standard infusion time of approximately three to four hours Results from the phase IV GAZELLE study showed no new safety signals with the shorter infusion of Gazyvaro Shorter infusions could be... Read more

October 13, 2021 Clinical Research/Diagn. Licensing, IP, and Legal

Agilent Receives FDA Companion Diagnostic Approval for Ki-67 IHC MIB-1 pharmDx in High-Risk Early Breast Cancer

SANTA CLARA, Calif., October 13, 2021  Agilent Technologies Inc. (NYSE: A) today announced its Ki-67 IHC MIB-1 pharmDx (Dako Omnis) is now FDA approved as an aid in identifying patients with early breast cancer (EBC) at high risk of disease recurrence, for whom adjuvant treatment with Verzenio® (abemaciclib) in combination with endocrine therapy is being considered.... Read more

October 13, 2021 Clinical Research/Diagn. M&A, Partnerships

GE Healthcare Partners with Apprise Health Insights to Launch Nation's First Automated Statewide Hospital Bed Management Solution in Oregon

First-of-its-kind tool actively manages hospital data, providing near real-time occupancy information that enables hospitals to maximize resources Saved participating hospitals 45,000 hours of labor, amounting to $3 million dollars, by eliminating the need for manual entry of capacity data Puts actionable data in the hands of decision-makers so that statewide capacity can be optimized, allowing... Read more

October 13, 2021 Licensing, IP, and Legal

Data up to 8-years for Roche’s OCREVUS (ocrelizumab) show early and ongoing treatment significantly reduced risk of requiring a walking aid in relapsing multiple sclerosis and disability progression in primary progressive multiple sclerosis

35% reduction in risk of needing a walking aid in relapsing multiple sclerosis (RMS) after 7.5 years vs. initiation 2 years later in Phase III open-label extension (OLE) 29% reduction in 48-week confirmed disability progression in primary progressive MS (PPMS) after 8 years vs. initiation after double-blind period in Phase III OLE New 8-year safety... Read more

October 12, 2021 Informatics & Software M&A, Partnerships

Fluidigm Announces New Co-Marketing Program under Collaboration Agreement with Visiopharm, Offering AI-Based Image Analysis Software

Oct 12, 2021 Native Reading of Hyperion Imaging System Data Files on the Visiopharm Platform to Streamline Data Analysis for Researchers SOUTH SAN FRANCISCO, Calif., Oct. 12, 2021 (GLOBE NEWSWIRE) — Fluidigm Corporation (NASDAQ:FLDM), an innovative biotechnology tools provider with a vision to improve life through comprehensive health insight, today announced a new co-marketing program to offer Visiopharm® image... Read more